专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2004110435A1 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES 审中-公开
标题翻译： 1-苯基-2-氧代-3-磺酰氨基吡咯烷酮衍生物及相关化合物作为治疗急性血管疾病的因子XA抑制剂
公开(公告)号：WO2004110435A1
公开(公告)日：2004-12-23
申请号：PCT/EP2004/006592
申请日：2004-06-17
申请人： GLAXO GROUP LIMITED , BORTHWICK, Alan, David , CHAN, Chuen , KELLY, Henry, Anderson , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , WATSON, Nigel, Stephen
发明人： BORTHWICK, Alan, David , CHAN, Chuen , KELLY, Henry, Anderson , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , WATSON, Nigel, Stephen
IPC分类号： A61K31/4025
CPC分类号： C07D413/14 , C07D409/12 , C07D409/14
摘要： The invention relates to compounds of formula (I) wherein: R 1 represents a group selected from: formula (II) each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents S, O or NH; R 2 represents -C 1-6 alkyl, -C 1-3 alkylCN, -C 0-3 alkylR c , -C 1-3 alkylR f , -C 2-3 alkylNR a R b , -C 2-3 alkylOC 1-6 alkyl, -C 2-3 alkylOC 1-3 alkylCONR a R b , with the proviso that R 2 does not represent C 2-3 alkylmorpholino; X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C 1-4 alkyl, -C 2-4 alkenyl, -CN, -CF 3 , -NR a R b , -C 0-4 alkylOR e , -C(O)R d and -C(O)NR a R b ; Y represents a substituent selected from hydrogen, halogen, -C 1-4 alkyl, -C 2-4 alkenyl, -NR a R b , -NO 2 , -C(O)NR a R b , -N(C 1-4 alkyl)(CHO), -NHCOC 1-4 alkyl, -NHSO 2 R d , -C 0-4 alkylOR e , -C(O)R d , -S(O) n R d , or -S(O) 2 NR a R b ; The other substituents are as defined in claim 1.
摘要翻译：本发明涉及式（I）化合物，其中：R 1表示选自以下的基团：式（II）其各环任选含有另外的杂原子N，Z表示任选的取代基卤素，alk表示亚烷基或亚烯基， T表示S，O或NH; R 2表示-C 1-6烷基，-C 1-3烷基CN，-C 0-3烷基，R c，-C 1-3烷基R f，-C 2 - 3烷基，NR a R b，-C 2 - 3烷基，C 1-6烷基， -C 2-3烷基OC 1-3烷基CONR a R a，条件是R 2不表示C 2-3烷基吗啉代; X表示苯基或含有至少一个选自O，N或S的杂原子的5-或6-元芳族杂环基团，每个选自O，R，C 1-4烷基，-C 2 - 烷基，-C（O）R d和-C（O）NR a R b， ; Y表示选自氢，卤素，-C 1-4烷基，-C 2-4链烯基，-NR a R b，-NO 2，-C（O）NR a R b，-N（ C 1-4烷基）（CHO），-NHCOC 1-4烷基，-NHSO 2 R d，-C 0-4烷基OR e，-C（O）R d，-S（O）n R d或-S （O）2 NR - [R的; 其它取代基如权利要求1中所定义。

12. 发明申请

WO2002100830A1 PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS 审中-公开
标题翻译：吡咯烷酮衍生物作为因子XA抑制剂
公开(公告)号：WO2002100830A1
公开(公告)日：2002-12-19
申请号：PCT/GB2002/002721
申请日：2002-06-06
申请人： GLAXO GROUP LIMITED , CHAN, Chuen , HAMBLIN, Julie, Nicole , KELLY, Henry, Anderson , KING, Nigel, Paul , MASON, Andrew, McMurtrie , PATEL, Vipulkumar, Kantibhai , SENGER, Stefan , SHAH, Gita, Punjabhai , WATSON, Nigel, Stephen , WESTON, Helen, Elisabeth , WHITWORTH, Caroline , YOUNG, Robert, John
发明人： CHAN, Chuen , HAMBLIN, Julie, Nicole , KELLY, Henry, Anderson , KING, Nigel, Paul , MASON, Andrew, McMurtrie , PATEL, Vipulkumar, Kantibhai , SENGER, Stefan , SHAH, Gita, Punjabhai , WATSON, Nigel, Stephen , WESTON, Helen, Elisabeth , WHITWORTH, Caroline , YOUNG, Robert, John
IPC分类号： C07D207/26
CPC分类号： C07D413/14 , A61K31/5377 , C07D207/12 , C07D413/06 , C07D417/14 , C07D495/04
摘要： The invention relates to compounds of formula (I) which processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
摘要翻译：本发明涉及其制备方法的式（I）化合物，含有它们的药物组合物及其在医药中的用途，特别是用于改善指示因子Xa抑制剂的临床病症。

13. 发明申请

WO2007017262A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS 审中-公开
标题翻译： XANTHINE衍生物作为选择性HM74A激动剂
公开(公告)号：WO2007017262A1
公开(公告)日：2007-02-15
申请号：PCT/EP2006/007869
申请日：2006-08-08
申请人： SMITHKLINE BEECHAM CORPORATION , HATLEY, Richard, Jonathan, Daniel , HEER, Jag, Paul , LIDDLE, John , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo , RAHMAN, Shahzad, Sharooq , SMITH, Ian, Edward, David
发明人： HATLEY, Richard, Jonathan, Daniel , HEER, Jag, Paul , LIDDLE, John , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo , RAHMAN, Shahzad, Sharooq , SMITH, Ian, Edward, David
IPC分类号： C07D473/06 , C07D473/04 , A61K31/495 , A61P3/00 , A61P9/00
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to compounds 0f formula (I), which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
摘要翻译：本发明涉及式（I）化合物，其为黄嘌呤衍生物，制备所述衍生物的方法，含有活性化合物的药物制剂以及该化合物在治疗中的用途，例如用于治疗下列疾病 HM74A受体的活化有助于疾病或受体活化将是有益的。

14. 发明申请

WO2007017261A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS 审中-公开
标题翻译： XANTHINE衍生物作为选择性HM74A激动剂
公开(公告)号：WO2007017261A1
公开(公告)日：2007-02-15
申请号：PCT/EP2006/007865
申请日：2006-08-08
申请人： SMITHKLINE BEECHAM CORPORATION , HATLEY, Richard, Jonathan, Daniel, , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo
发明人： HATLEY, Richard, Jonathan, Daniel, , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo
IPC分类号： C07D473/06 , C07D473/04 , A61K31/495 , A61P3/00 , A61P9/00
CPC分类号： C07D473/04 , C07D473/06
摘要： The present invention relates to compounds1 of formula (I) which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these, compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
摘要翻译：本发明涉及作为黄嘌呤衍生物的式（I）化合物1，制备所述衍生物的方法，含有这些衍生物的药物制剂，化合物和该化合物在治疗中的用途，例如用于治疗疾病， HM74A受体的激活有助于该疾病或受体活化将是有益的。

15. 发明申请

WO2006085108A1 AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA 审中-公开
标题翻译：戊二酸衍生物及其用于治疗脂质代谢疾病，特别是DYSLIPIDAEMIA
公开(公告)号：WO2006085108A1
公开(公告)日：2006-08-17
申请号：PCT/GB2006/000499
申请日：2006-02-14
申请人： SMITHKLINE BEECHAM CORPORATION , CAMPBELL, Mathew , MASON, Andrew, Mcmurtrie , PINTO, Ivan, Leo , POLLARD, Derek, Roland , SMITH, Ian, Edward, David
发明人： CAMPBELL, Mathew , MASON, Andrew, Mcmurtrie , PINTO, Ivan, Leo , POLLARD, Derek, Roland , SMITH, Ian, Edward, David
IPC分类号： C07D319/18 , C07D215/20 , C07D271/10 , C07D277/20 , C07D277/68 , A61K31/33 , A61P9/10
CPC分类号： C07D241/44 , C07D215/12 , C07D217/22 , C07D253/10 , C07D277/82 , C07D285/08 , C07D295/215 , C07D333/66
摘要： Therapeutically active anthranilic acid derivatives of Formula (I) wherein R 1 , R 2 , W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
摘要翻译：式（I）的其中R 1，R 2，W，Y和Z的治疗活性的邻氨基苯甲酸衍生物如说明书中所定义，用于制备所述衍生物的方法公开了含有活性化合物的药物制剂和该药物在治疗中的用途，特别是用于治疗其中HM74A受体的未激活有助于疾病或受体活化将是有益的疾病。

16. 发明申请

WO2006000759A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS 审中-公开
标题翻译：替代哌替啶作为氧化蛋白拮抗剂
公开(公告)号：WO2006000759A1
公开(公告)日：2006-01-05
申请号：PCT/GB2005/002448
申请日：2005-06-21
申请人： GLAXO GROUP LIMITED , BORTHWICK, Alan, David , HICKEY, Deirdre, Mary, Bernadette , LIDDLE, John , MASON, Andrew McMurtrie , POLLARD, Derek, Roland , SOLLIS, Steven
发明人： BORTHWICK, Alan, David , HICKEY, Deirdre, Mary, Bernadette , LIDDLE, John , MASON, Andrew McMurtrie , POLLARD, Derek, Roland , SOLLIS, Steven
IPC分类号： C07D401/06
CPC分类号： C07D401/06 , C07D403/06 , C07D413/06
摘要： Compounds of formula (I); wherein R 1 is 2-indanyl, R 2 is 1-ethylpropyl, R 3 is a heterocyclic group optionally substituted by one or more C 1-6 alkyl groups, R 4 represents methyl and R 5 represents hydrogen or methyl and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
摘要翻译：式（I）化合物; 其中R 1是2-二氢化茚基，R 2是1-乙基丙基，R 3是任选地被一个或多个C 1 - SUB> 1-6个烷基，R 4代表甲基，R 5表示氢或甲基，其药学上可接受的衍生物被描述为它们的制剂，含有它们的药物组合物及其在医药中的用途，特别是其作为催产素拮抗剂的用途。

17. 发明申请

WO2005016870A1 2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS 审中-公开
标题翻译：作为HM74A受体激动剂的2-取代苯甲酸衍生物
公开(公告)号：WO2005016870A1
公开(公告)日：2005-02-24
申请号：PCT/GB2004/003528
申请日：2004-08-13
申请人： SMITHKLINE BEECHAM CORPORATION , CAMPBELL, Mathew , HATLEY, Richard, Jonathan , HEER, Jag, Paul , MASON, Andrew, McMurtrie , NICHOLSON, Neville, Hubert , PINTO, Ivan, Leo , RAHMAN, Shahzad, Sharooq , SMITH, Ian, Edward, David
发明人： CAMPBELL, Mathew , HATLEY, Richard, Jonathan , HEER, Jag, Paul , MASON, Andrew, McMurtrie , NICHOLSON, Neville, Hubert , PINTO, Ivan, Leo , RAHMAN, Shahzad, Sharooq , SMITH, Ian, Edward, David
IPC分类号： C07C235/38
CPC分类号： C07D231/12 , C07C233/55 , C07C235/24 , C07C235/38 , C07C235/78 , C07C237/12 , C07C311/21 , C07D213/65 , C07D271/06 , C07D307/52 , C07D333/24
摘要： Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.
摘要翻译：式（I）的治疗活性的邻氨基苯甲酸衍生物，其中R1，R2和Z如说明书中所定义，所述衍生物的制备方法，含有活性化合物的药物制剂以及该化合物在治疗中的用途，特别是在治疗中公开了其中HM74A受体的未激活有助于疾病或受体激活将是有益的疾病。

18. 发明申请

WO02100886A8 PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA 审中-公开
标题翻译：吡咯烷-2-酮衍生物作为因子XA的抑制剂
公开(公告)号：WO02100886A8
公开(公告)日：2004-02-05
申请号：PCT/GB0202586
申请日：2002-06-06
申请人： GLAXO GROUP LTD , CHAN CHUEN , HAMBLIN JULIE NICOLE , KELLY HENRY ANDERSON , KING , MASON ANDREW MCMURTRIE , PATEL VIPULKUMAR KANTIBHAI , SENGER STEFAN , SHAH GITA PUNJABHAI , WATSON NIGEL STEPHEN , WESTON HELEN ELISABETH , WHITWORTH CAROLINE , YOUNG ROBERT JOHN
发明人： CHAN CHUEN , HAMBLIN JULIE NICOLE , KELLY HENRY ANDERSON , KING , MASON ANDREW MCMURTRIE , PATEL VIPULKUMAR KANTIBHAI , SENGER STEFAN , SHAH GITA PUNJABHAI , WATSON NIGEL STEPHEN , WESTON HELEN ELISABETH , WHITWORTH CAROLINE , YOUNG ROBERT JOHN
IPC分类号： C07D487/08 , A61K31/4025 , A61K31/407 , A61K31/4365 , A61K31/437 , A61K31/439 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K38/00 , A61K38/55 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07D207/273 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/12 , C07D409/12 , C07D413/06 , C07D417/14 , C07D471/04 , C07D471/08 , C07D491/08 , C07D495/04 , C07D498/08 , C07K5/06 , C07K5/078
CPC分类号： A61K9/0031 , A61K9/0019 , A61K9/0024 , A61K9/0043 , A61K9/0056 , A61K9/0073 , A61K9/0095 , A61K9/02 , A61K9/12 , A61K31/4025 , A61K31/454 , A61K38/00 , C07K5/06034 , C07K5/06139 , C07K5/06191
摘要： The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
摘要翻译：本发明涉及式（Ic）化合物的制备方法，含有它们的药物组合物及其在药物中的用途，特别是用于改善指定因子Xa抑制剂的临床病症。

19. 发明申请

WO2003053925A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS 审中-公开
标题翻译：吡咯烷-2-酮作为因子XA抑制剂
公开(公告)号：WO2003053925A1
公开(公告)日：2003-07-03
申请号：PCT/EP2002/014826
申请日：2002-12-20
申请人： GLAXO GROUP LIMITED , BORTHWICK, Alan, David , CHAN, Chuen , KELLY, Henry, Anderson , KING, Nigel, Paul , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo , POLLARD, Derek, Roland , SENGER, Stefan , SHAH, Gita, Punjabhai , WATSON, Nigel, Stephen , YOUNG, Robert, John
发明人： BORTHWICK, Alan, David , CHAN, Chuen , KELLY, Henry, Anderson , KING, Nigel, Paul , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , PINTO, Ivan, Leo , POLLARD, Derek, Roland , SENGER, Stefan , SHAH, Gita, Punjabhai , WATSON, Nigel, Stephen , YOUNG, Robert, John
IPC分类号： C07D207/273
CPC分类号： C07D207/273 , C07D401/12 , C07D403/10 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D417/04
摘要： The invention relates to compounds of formula (I): , and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
摘要翻译：本发明涉及式（I）化合物：及其药学上可接受的衍生物。本发明还涉及制备式（I）化合物的方法，包含式（I）化合物的药物组合物和式（I）化合物在医药中的用途，特别是在改善临床病症方面指示因子Xa抑制剂。

20. 发明申请

WO2003043981A1 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS 审中-公开
标题翻译： 2-（3-磺酰氨基-2-氧代吡咯烷-1-基）丙酰胺作为因子XA抑制剂
公开(公告)号：WO2003043981A1
公开(公告)日：2003-05-30
申请号：PCT/GB2002/005134
申请日：2002-11-13
申请人： GLAXO GROUP LIMITED , BORTHWICK, Alan, David , CAMPBELL, Matthew , CHAN, Chuen , KELLY, Henry, Anderson , KING, Nigel, Paul , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , SENGER, Stefan , SMITH, Paul, William , WATSON, Nigel, Stephen , YOUNG, Robert, John
发明人： BORTHWICK, Alan, David , CAMPBELL, Matthew , CHAN, Chuen , KELLY, Henry, Anderson , KING, Nigel, Paul , KLEANTHOUS, Savvas , MASON, Andrew, McMurtrie , SENGER, Stefan , SMITH, Paul, William , WATSON, Nigel, Stephen , YOUNG, Robert, John
IPC分类号： C07D207/26
CPC分类号： C07D207/273 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14
摘要： The invention relates to compounds of formula (I), wherein: R 1 represents hydrogen or -C 1-3 alkylCONR a R b ; One of R 2 and R 3 represents -C 1-3 alkyl and the other represents hydrogen; R 4 represents hydrogen, -C 1-4 alkyl, -C 3-4 alkenyl, -C 2-4 alkylOH, -C 2-4 alkylOC 1-4 alkyl, -C 1-4 alkylCN or -C 0-4 alkylC 3-6 cycloalkyl; R 5 represents -C 2-4 alkylOH, -C 1-4 alkyl, -C 2-4 alkylOC 1-4 alkyl, -C 1-4 alkylCN, -C 1-4 alkylCONR c R d , -C 2-4 alkylNR a R b , -C 2-4 alkylNHCOC 1-3 alkyl, -C 2-4 alkylNHCONR a R b , -C2-4alkylNHSO 2 R e , -C 2-4 alkylSO 2 NR a R b , -C 2-4 alkylNHCO 2 C 1-4 alkyl, -C 2-4 alkylNHC(NH 2 )=NR f , or a group X-Y; X represents -C 1-4 alkylene- optionally substitued by -OH, or a direct link, with the proviso that when X is substituted by -OH, X represents C 2-4 alkylene and the -OH group is not alpha with respect to the amide N atom to which the group X is attached; Y represents -C 3-6 cycloalkyl, phenyl, or an aromatic or non-aromatic 5-, 6- or 7-membered heterocyclic group containing at least one heteroatom selected from O, N or S and optionally substituted at C and/or N atoms by -C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylOH, halogen, -CN, -CF 3 , -NH 2 , -CO 2 H and -OH; R a and R b independently represent hydrogen or -C 1-4 alkyl; R c and R d independently represent hydrogen or -C 1-4 alkyl or together with the N atom to which they are attached form a non-aromatic 5-, 6- or 7- membered heterocyclic group optionally substituted by a heteroatom selected from O, N or S; R e represents -C 1-4 alkyl or -CF 3 ; R f represents NO 2 or CN; R 6 represents a group selected from: (i), (ii), (iii), (iv), (v), Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents a heteroatom selected from S or N; and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
摘要翻译：本发明涉及式（I）化合物，其中：R 1表示氢或-C 1-3烷基CONR a R b; R 2和R 3中的一个表示-C 1-3烷基，另一个表示氢; R 4表示氢，-C 1-4烷基，-C 3-4链烯基，-C 2-4烷基，C 2-4烷基，C 1-4烷基，-C 1-4烷基，或C 0-4烷基。 R 5表示-C 2-4芳烷基，C 1-4烷基，-C 2-4烷基，C 1-4烷基，-C 1-4烷基，C 1-4烷基，C R 6，-C 2-4烷基，NR a R b，，-C2-4烷基NHCOC1-3烷基，-C2-4烷基NHCORRαR2，-C2-4烷基NHSO2R5，-C2-4烷基，SO2NR，R2，-C2-4烷基，NHCO2C1-4烷基， 4烷基NH（NH 2）= NR或基团XY; X代表-C 1-4亚烷基 - 任选被-OH取代或直接连接，条件是当X被-OH取代时，X代表C2-4亚烷基，-OH基团相对于酰胺N原子不是α 组X连接到其上; Y代表-C3-6环烷基，苯基或含有至少一个选自O，N或S的杂原子的芳族或非芳族的5元，6元或7元杂环基，并且任选地在C和/或N原子被C -C 1-3烷基，C 1-3烷氧基，C 1-3烷基OH，卤素，-CN，-CF 3，-NH 2，-CO 2 H和-OH; R a和R b独立地表示氢或-C 1-4烷基; R c和R d独立地表示氢或-C 1-4烷基或与它们所连接的N原子一起形成任选被被选定的杂原子取代的非芳香族5-，6-或7-元杂环基来自O，N或S; R e表示-C 1-4烷基或-CF 3; R表示NO2或CN; R 6表示选自以下的基团：（i），（ii），（iii），（iv），（v），Z表示任选的取代基卤素，alk表示亚烷基或亚烯基，T表示选自S 或N; 及其药学上可接受的衍生物。本发明还涉及制备式（I）化合物的方法，包含式（I）化合物的药物组合物和式（I）化合物在医药中的用途，特别是在改善临床病症方面指示因子Xa抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式